These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 17641778

  • 41. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

  • 42. Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB.
    Govindarajan B, Shah A, Cohen C, Arnold RS, Schechner J, Chung J, Mercurio AM, Alani R, Ryu B, Fan CY, Cuezva JM, Martinez M, Arbiser JL.
    J Biol Chem; 2005 Apr 08; 280(14):13936-43. PubMed ID: 15695519
    [Abstract] [Full Text] [Related]

  • 43. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.
    Semela D, Das A, Langer D, Kang N, Leof E, Shah V.
    Gastroenterology; 2008 Aug 08; 135(2):671-9. PubMed ID: 18570897
    [Abstract] [Full Text] [Related]

  • 44. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB.
    Cheng X, Jin Z, Ji X, Shen X, Feng H, Morgenlander W, Ou B, Wu H, Gao H, Ye F, Zhang Y, Peng Y, Liang J, Jiang Y, Zhang T, Qiu W, Lu X, Zhao R.
    Int J Cancer; 2019 Jul 01; 145(1):179-191. PubMed ID: 30650178
    [Abstract] [Full Text] [Related]

  • 45. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.
    Cancer Biol Ther; 2010 Feb 01; 9(3):176-82. PubMed ID: 20009575
    [Abstract] [Full Text] [Related]

  • 46. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
    Rosenberg A, Mathew P.
    Expert Opin Investig Drugs; 2013 Jun 01; 22(6):787-94. PubMed ID: 23540855
    [Abstract] [Full Text] [Related]

  • 47. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
    Jain RK, Lahdenranta J, Fukumura D.
    PLoS Med; 2008 Jan 29; 5(1):e24. PubMed ID: 18232729
    [Abstract] [Full Text] [Related]

  • 48. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.
    Blood; 2013 Jun 27; 121(26):5192-202. PubMed ID: 23632889
    [Abstract] [Full Text] [Related]

  • 49. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.
    Cancer Res; 2009 May 15; 69(10):4527-36. PubMed ID: 19401451
    [Abstract] [Full Text] [Related]

  • 50. Pericyte-fibroblast transition promotes tumor growth and metastasis.
    Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, Hartman J, Religa P, Morikawa H, Ishii Y, Sasahara M, Larsson O, Cossu G, Cao R, Lim S, Cao Y.
    Proc Natl Acad Sci U S A; 2016 Sep 20; 113(38):E5618-27. PubMed ID: 27608497
    [Abstract] [Full Text] [Related]

  • 51. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas.
    Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, Lang FF.
    Neurosurgery; 2010 Jan 20; 66(1):144-56; discussion 156-7. PubMed ID: 20023545
    [Abstract] [Full Text] [Related]

  • 52. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN, Karamanos NK.
    FEBS J; 2013 May 20; 280(10):2477-89. PubMed ID: 23374223
    [Abstract] [Full Text] [Related]

  • 53. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
    George D.
    Adv Exp Med Biol; 2003 May 20; 532():141-51. PubMed ID: 12908555
    [Abstract] [Full Text] [Related]

  • 54. PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer.
    Kimura Y, Inoue K, Abe M, Nearman J, Baranowska-Kortylewicz J.
    Cancer Biol Ther; 2007 Nov 20; 6(11):1763-72. PubMed ID: 17986854
    [Abstract] [Full Text] [Related]

  • 55. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer.
    Ebert M, Yokoyama M, Friess H, Kobrin MS, Büchler MW, Korc M.
    Int J Cancer; 1995 Sep 04; 62(5):529-35. PubMed ID: 7665222
    [Abstract] [Full Text] [Related]

  • 56. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U, Christofferson R.
    Pediatr Res; 2005 May 04; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [Abstract] [Full Text] [Related]

  • 57. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development.
    Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, Stenzel D, Sauvaget D, Ledin J, Ringvall M, Landegren U, Kjellén L, Bondjers G, Li JP, Lindahl U, Spillmann D, Betsholtz C, Gerhardt H.
    Genes Dev; 2007 Feb 01; 21(3):316-31. PubMed ID: 17289920
    [Abstract] [Full Text] [Related]

  • 58. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [Abstract] [Full Text] [Related]

  • 59. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
    Apte SM, Fan D, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2004 Feb 01; 10(3):897-908. PubMed ID: 14871965
    [Abstract] [Full Text] [Related]

  • 60. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH.
    Cancer Res; 2001 Aug 01; 61(15):5778-83. PubMed ID: 11479215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.